EGFR and non-small cell lung carcinoma: The 3.8-month extension in the median PFS EGFR TKI plus anlotinib overo EGFR TKI only occurred in EGFR mutant NSCLC patients who have already developed resistance while on first-line third-generation EGFR TKI, a class known for deep and durable responses.